Rocket Pharmaceuticals Inc

XNAS:RCKT

3.47

+0.13 (+3.89%)

7:34:03 PM EDT: $3.41 -0.06 (-1.73%)

Market Cap (Intraday)	395.74M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.39 Million
Adjusted EPS	-$0.40

See more estimates

10-Day MA	$3.44
50-Day MA	$3.35
200-Day MA	$3.56

See more pivots

Rocket Pharmaceuticals Inc Stock, XNAS:RCKT

9 Cedarbrook Drive, 350 5th Avenue, Cranbury, New Jersey 08512

United States of America

Phone: +1.609.659.8001

Number of Employees: 299

http://www.rocketpharma.com

Description

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.